Day 2 will cover how advances in areas such as genome-editing, RNA-based medicine, cellular therapies and regenerative medicine, and the advent of other new technology are impacting therapeutic developments. Examples from the field of oncology will serve as illustrations of the revolution in health arising from these. An important theme will be the ability to accelerate health improvements through partnership between academia and industry.

April 9 - Day 2	From precision health to new diagnostics and therapies
Time	Title	Speakers
Chair	Ichiro Taniuchi
09:15-09:45	From viruses to extracellular vesicles: unleashing their potential as next-generation drug delivery platforms	Carolina Ilkow, Ottawa Hospital Research Institute
09:45-10:15	mRNA-based therapeutics : current status and future perspective	Shrio Akinaga, NANO MRNA
10:15-10:45	Regeneration of thymic function using iPSC technology: towards overcoming T-cell aging	Yoko Hamazaki, Kyoto University
Break
Chair	Ioannis Ragoussis
11:00-11:30	HORIBA’s vision and challenges for the life sciences	Yoko Nakai, HORIBA
11:30-12:00	Towards better diagnostics and biomarkers: microfluidics, 3D printing, and single extracellular vesicle analysis	David Juncker, McGill
12:00-12:30	Shimadzu's life science project	Makoto Watanabe, Shimadzu
Lunch
Chair	Sidong Huang
13:30-14:00	Precision genome editing screening to enquire protein function	Raquel Cuella Martin, McGill
14:00-14:30	Tackling oncohistone pathogenesis at the root in cancer	Nada Jabado, McGIll
14:30-15:00	Engineering robustness in stem and immune cell therapy	Fumihiko Ishikawa, RIKEN
15:00-15:30	Metabolomics in human studies and the discovery of bioactive microbial metabolites	Marc Dumas, Imperial College London
Break
Chair	Fumihiko Ishikawa
16:00-16:30	Biology of LipoQuality and the Lipidome Atlas	Makoto Arita, RIKEN
16:30-17:00	Innovations in biomedicine	Rami Suzuki, ARC Therapies
17:00-17:30	Keynote: Modality strategy in pharma industry	Wataru Takasaki, Daiichi-Sankyo